Beta-lactam
and Beta-lactamase Inhibitors Market share is estimated $27.12 billion in 2018, and
is anticipated to touch $34.17 billion by 2028, recording a CAGR of
2.3% from 2019 to 2028.
Growth
in the global beta-lactam and beta-lactamase inhibitor market is driven by a
surge in consumption in low- and middle-income countries (LMIC), increased
prevalence of infectious diseases, and adoption of new approaches for the
treatment of bacterial infections Will be promoted. However, the tremendous
amount of time needed to develop beta-lactam resistance and to be approved by
regulatory agencies will hinder market growth. Meanwhile, innovative
combination therapies for the discovery of highly promising molecules and the
treatment of antibiotic-resistant microbial infections offer new opportunities
on the market.
Worldwide
leaders
- Abbott
Laboratories
- Allergan
Plc.
- F.
Hoffmann-La Roche Ltd.
- GlaxoSmithKline
plc
- Merck
& Co. Inc.
- Mylan
N.V.
- Novartis
International AG (Sandoz)
- Pfizer
Inc.
- Sanofi
- Teva
Pharmaceutical Industries Ltd.
Based
on drug class, the cephalosporin segment held the highest share in the global
beta-lactam and beta-lactamase inhibitor market in 2018, accounting for nearly
two-fifths of the total share, and its status throughout the forecast period Is
expected to maintain. This is due to the broad spectrum activity and the
development of the next generation cephalosporin to combat antimicrobial
resistance. On the other hand, the combined segment from 2019 to 2028 will grow
at the fastest growth rate with a CAGR of 4.6% due to the increased prevalence
of antimicrobial resistance and the incidence of chronic diseases.
Based
on disease, the respiratory infection segment has a large share of the global
beta-lactam and beta-lactamase inhibitor market in 2018, contributing more than
one-fifth of the total share, and forecast period The terms of revenue during.
This is due to an increase in the prevalence of lung disease and a surge in
research and development of therapeutics for respiratory infections. However,
the complex intraperitoneal infection (cIAI) segment is expected to grow at a
CAGR of up to 4.8% from 2020 to 2030. This is due to the increased burden of
sepsis and the rapid increase in mortality.
Asia-Pacific
accounts for nearly two-fifths of total market share in 2018 and is estimated
to maintain that share during the forecast period. This is due to the surge in
the consumption of antibiotics, the availability of antibiotics, and the
increase in sales of antibiotics without a prescription. North America had
approximately a quarter of the total market share of beta-lactam and
beta-lactamase inhibitors in 2018. The availability of antibiotics
over-the-counter and the lack of laws or restrictions on local use.
No comments:
Post a Comment